Such decisions require thorough assessment of potential benefits, risks, contraindications, and monitoring requirements
BMJ Meta-Analysis (2014): Among 353,639 patients, pooled odds ratios showed no excess risk of pancreatitis for either GLP-1 agonists or DPP-4 inhibitors
The control group was significantly different than the current time point for both medications (Semaglutide: B = 10.29, SE = 3.02, p = 0.004, Tirzepatide: B = 11.445, SE = 3.08, p = 0.003), but was not different when compared to prior to starting each medication (n.s.)
The roles of LRP5 and LRP6 in osteogenesis remain debated
You found this not helpful 0 of 0 found this helpful Berry Blast Show More + Show Less - ERAN M Use this every time before cardio and sweat like never before
While the risk of interaction due to delayed digestion is real, it is often manageable with the right clinical oversight